Addiction Medicine
Latest News
Tranq-contaminated fentanyl now in 48 states, DEA warns
Xylazine was first approved by the FDA in 1972 as a sedative and analgesic for use only in animals, but is increasingly being detected in illicit...
News
FDA approves OTC naloxone, but will cost be a barrier?
“The major question is what is it going to cost. In order for people to access it they have to be able to afford it,”
News
Watch for buprenorphine ‘spiking’ in urine drug tests
Some patients undergoing treatment for opioid use disorder alter their urine drug test results by adding buprenorphine directly to their urine.
News
Substance abuse disorders may share a common genetic signature
New findings could eventually lead to universal therapies to treat multiple and comorbid addictions, according to the study’s authors.
Latest News
Opioid overdose is an important cause of postpartum death
Ob.gyns. have an opportunity to screen patients to identify those at high risk for opioid use disorder or opioid overdose, and a new law eases...
News
FDA moves to stop the spread of illicit ‘tranq’ in the U.S.
The agency “remains concerned about the increasing prevalence of xylazine mixed with illicit drugs,” said FDA Commissioner Robert M. Califf, MD....
Latest News
DEA proposals on telehealth for controlled substances draw fire
Both proposals would allow providers to prescribe a 30-day supply of a controlled substance or buprenorphine, but then require a face-to-face...
News
Buprenorphine proves effective for fentanyl users in the ED
A new study provides additional information about emergency department buprenorphine as fentanyl becomes increasingly prevalent.
Commentary
The SHOW UP Act Threatens VA Telehealth
Commentary
Joint effort: CBD not just innocent bystander in weed
‘I visited a legal cannabis dispensary in Massachusetts a few years ago, mostly to see what the hype was about.’